Resonance Specialities Ltd
Incorporated in 1989, Resonance Specialties Ltd manufactures Pyridine, Picoline, Cynopyridine and derivatives of the same[1]
- Market Cap ₹ 104 Cr.
- Current Price ₹ 90.0
- High / Low ₹ 124 / 65.0
- Stock P/E 13.9
- Book Value ₹ 57.3
- Dividend Yield 1.11 %
- ROCE 15.4 %
- ROE 11.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 6.75% over past five years.
- Company has a low return on equity of 8.78% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.30 | 37.84 | 38.63 | 33.91 | 35.71 | 41.40 | 56.14 | 70.29 | 75.76 | 57.98 | 54.82 | 77.81 | 85.24 | |
| 42.19 | 36.59 | 35.62 | 31.89 | 35.06 | 36.51 | 48.39 | 56.04 | 59.01 | 51.15 | 50.00 | 67.03 | 74.16 | |
| Operating Profit | 3.11 | 1.25 | 3.01 | 2.02 | 0.65 | 4.89 | 7.75 | 14.25 | 16.75 | 6.83 | 4.82 | 10.78 | 11.08 |
| OPM % | 6.87% | 3.30% | 7.79% | 5.96% | 1.82% | 11.81% | 13.80% | 20.27% | 22.11% | 11.78% | 8.79% | 13.85% | 13.00% |
| -0.38 | 1.86 | 0.26 | 0.82 | 1.08 | 1.31 | 0.44 | 1.59 | 1.36 | 1.61 | 0.93 | 0.01 | 0.95 | |
| Interest | 0.59 | 0.58 | 0.52 | 0.39 | 0.55 | 0.54 | 0.35 | 0.29 | 0.07 | 0.11 | 0.33 | 0.35 | 0.28 |
| Depreciation | 1.10 | 1.16 | 1.12 | 1.06 | 1.15 | 0.91 | 0.92 | 0.98 | 1.75 | 1.48 | 1.46 | 1.56 | 1.25 |
| Profit before tax | 1.04 | 1.37 | 1.63 | 1.39 | 0.03 | 4.75 | 6.92 | 14.57 | 16.29 | 6.85 | 3.96 | 8.88 | 10.50 |
| Tax % | 0.96% | 7.30% | 27.61% | 25.90% | 2,700.00% | 32.63% | 20.38% | 27.73% | 24.06% | 27.01% | 25.00% | 26.13% | |
| 1.03 | 1.28 | 1.19 | 1.03 | -0.77 | 3.20 | 5.51 | 10.52 | 12.36 | 5.00 | 2.97 | 6.57 | 7.47 | |
| EPS in Rs | 0.89 | 1.11 | 1.03 | 0.89 | -0.67 | 2.77 | 4.77 | 9.11 | 10.71 | 4.33 | 2.57 | 5.69 | 6.47 |
| Dividend Payout % | 56.02% | 45.08% | 0.00% | 0.00% | 0.00% | 0.00% | 20.94% | 10.97% | 9.34% | 23.08% | 0.00% | 17.56% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 7% |
| 3 Years: | 1% |
| TTM: | 27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 1% |
| 3 Years: | -17% |
| TTM: | 71% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 8% |
| 3 Years: | -12% |
| 1 Year: | -14% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 15% |
| 3 Years: | 9% |
| Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 | 11.54 |
| Reserves | 9.45 | 9.95 | 11.14 | 12.42 | 11.72 | 14.93 | 18.99 | 29.13 | 40.26 | 44.15 | 45.95 | 52.48 | 54.58 |
| 3.38 | 3.12 | 1.92 | 4.07 | 3.40 | 0.00 | 0.00 | 0.72 | 0.09 | 2.29 | 4.17 | 3.31 | 2.78 | |
| 9.77 | 9.95 | 7.76 | 11.75 | 10.19 | 11.70 | 10.60 | 13.25 | 4.89 | 7.81 | 12.12 | 8.22 | 12.33 | |
| Total Liabilities | 34.14 | 34.56 | 32.36 | 39.78 | 36.85 | 38.17 | 41.13 | 54.64 | 56.78 | 65.79 | 73.78 | 75.55 | 81.23 |
| 15.22 | 14.26 | 13.86 | 15.06 | 14.60 | 14.07 | 14.11 | 15.90 | 13.83 | 19.91 | 22.90 | 21.33 | 20.87 | |
| CWIP | 0.03 | 0.03 | 0.13 | 0.20 | 0.60 | 0.83 | 1.84 | 0.04 | 0.44 | 0.44 | 0.32 | 0.56 | 2.48 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.75 | 0.12 | 0.00 | 2.81 | 0.00 | 2.54 |
| 18.89 | 20.27 | 18.37 | 24.52 | 21.65 | 23.27 | 25.08 | 37.95 | 42.39 | 45.44 | 47.75 | 53.66 | 55.34 | |
| Total Assets | 34.14 | 34.56 | 32.36 | 39.78 | 36.85 | 38.17 | 41.13 | 54.64 | 56.78 | 65.79 | 73.78 | 75.55 | 81.23 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.76 | 1.11 | 3.23 | 0.56 | 2.14 | 5.27 | 1.42 | 4.28 | 13.33 | -8.37 | 4.16 | -2.51 | |
| -0.07 | -0.28 | -0.82 | -2.62 | -1.11 | -0.50 | -1.82 | -1.18 | -8.80 | 3.20 | -6.63 | 2.15 | |
| -0.60 | -1.52 | -2.41 | 1.76 | -1.01 | -3.65 | 1.15 | 0.31 | -1.86 | 0.93 | 0.33 | -1.20 | |
| Net Cash Flow | 1.09 | -0.69 | 0.01 | -0.30 | 0.02 | 1.11 | 0.76 | 3.42 | 2.66 | -4.24 | -2.13 | -1.56 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 76.63 | 99.16 | 66.05 | 79.76 | 67.97 | 66.74 | 39.92 | 48.92 | 39.51 | 77.68 | 88.69 | 104.94 |
| Inventory Days | 81.52 | 133.71 | 159.21 | 397.20 | 211.58 | 180.17 | 232.12 | 236.12 | 175.79 | 646.44 | 340.53 | 315.97 |
| Days Payable | 68.68 | 116.18 | 108.07 | 262.26 | 127.21 | 138.98 | 114.32 | 120.62 | 17.35 | 137.50 | 134.00 | 65.41 |
| Cash Conversion Cycle | 89.46 | 116.69 | 117.19 | 214.70 | 152.35 | 107.93 | 157.71 | 164.41 | 197.94 | 586.62 | 295.21 | 355.50 |
| Working Capital Days | 56.16 | 70.80 | 73.79 | 85.14 | 79.93 | 93.19 | 81.92 | 99.34 | 142.99 | 211.96 | 220.78 | 205.84 |
| ROCE % | 7.30% | 3.96% | 8.74% | 6.84% | 2.23% | 20.21% | 30.63% | 41.32% | 34.91% | 12.65% | 7.15% | 15.40% |
Documents
Announcements
-
Re-Lodgement Of Transfer Request Of Physical Shares
1d - Registrar reported zero re-lodgement requests for physical share transfers for month ended October 31, 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Results for the 2nd quarter and half year ended September 30, 2025 published in Newspaper.
- STANDALONE RESULTS FOR Q2 AND HALF YEAR ENDED 30.09.2025 3 Nov
-
Board Meeting Outcome for OUTCOME OF BOARD MEETING HELD ON 03.11.2025
3 Nov - Board approved Q2/H1 results (Sep 30, 2025): H1 revenue Rs4,280.77 lakh; H1 PAT Rs328.74 lakh
-
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 03/11/2025 To Consider And Approve Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2025.
15 Oct - Board meeting on Nov 3, 2025 to approve unaudited Q2 and half-year results (ended Sep 30, 2025); trading window closed.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
RSL is an integrated Product Development Company focusing on Pyridine and its derivatives. It also has expertise in organic
chemistry and expertise in catalysis.